26-07-2021, 09:32 AM
CureVac COVID-19 vaccine records only 48% efficacy in final trial readout
June 30 (Reuters) - CureVac (5CV.DE) said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass(40,000) trial, only marginally better than the 47% reported after an initial read-out two weeks ago.
https://www.reuters.com/business/healthc...021-06-30/
June 30 (Reuters) - CureVac (5CV.DE) said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass(40,000) trial, only marginally better than the 47% reported after an initial read-out two weeks ago.
https://www.reuters.com/business/healthc...021-06-30/